Add BrightSurf on Google Email

Oregon Health & Science University


OHSU, CDC unravel mysterious eye infection

A 26-year-old Oregon woman became the first known human to be infected with Thelazia gulosa, a type of cattle eyeworm, after possibly being bitten by an infected fly while fishing in Alaska. She underwent treatment at OHSU and removed all 14 worms from her eye over the course of a month.

SourceOregon Health & Science University·JournalAmerican Journal of Tropical Medicine and Hygiene·DateFeb 12, 2018

Researchers identify information gaps about opioid antidote naloxone

A systematic review of evidence reveals important gaps in knowledge about the safety and effectiveness of widespread off-label use of naloxone among patients, families, friends, and emergency responders. The study found that the majority of naloxone being administered nasally is probably the non-approved formulation, but little is know...

SourceOregon Health & Science University·JournalAnnals of Internal Medicine·DateNov 27, 2017

New England Journal of Medicine publishes long-term results of Gleevec®

A nearly 11-year follow-up study published in the New England Journal of Medicine shows an estimated overall survival rate of 83.3% among 1,106 patients with chronic myeloid leukemia treated with Gleevec. The treatment has been proven effective against multiple forms of cancer, including pediatric CML and gastrointestinal stromal tumor.

SourceOregon Health & Science University·JournalNew England Journal of Medicine·DateMar 8, 2017

Co-invented by OHSU's Dr. David Huang 25 years ago, OCT technology helps stop blindness

The Association for Research in Vision and Ophthalmology published a special issue commemorating the 25th anniversary of Optical Coherence Tomography (OCT) technology. OCT has revolutionized eye disease diagnosis and treatment, enabling early detection of devastating conditions like age-related macular degeneration and glaucoma.

SourceOregon Health & Science University·JournalInvestigative Ophthalmology & Visual Science·DateJul 14, 2016

Study finds first evidence that PD-1 antibody could help men with metastatic prostate cancer

Researchers at the OHSU Knight Cancer Institute have reported promising results from a Phase II clinical trial of pembrolizumab, a PD-1 antibody, in men with metastatic prostate cancer. Three out of ten participants showed significant responses to treatment, including rapid decreases in PSA levels and tumor shrinkage.

SourceOregon Health & Science University·JournalOncoTargets and Therapy·DateJul 13, 2016

Discovery of insulin-producing beta cell subtypes may impact diabetes treatment

Researchers have discovered at least four separate subtypes of human insulin-producing beta cells, which could lead to a better understanding of the disease process and the development of new treatments for type 2 diabetes. The study found that these cell subtypes produce different amounts of insulin and may regenerate at varying rates.

SourceOregon Health & Science University·JournalNature Communications·DateJul 11, 2016